İlknur Bingül1, Pervin Vural1, Semra Doğru-Abbasoğlu1, Esra Çil2, Müjdat Uysal1. 1. Istanbul Faculty of Medicine, Department of Biochemistry, Istanbul University, Istanbul, Turkey. 2. II. Internal Medicine Clinic, Department of Endocrinology, Şişli Etfal Education and Research Hospital, Istanbul, Turkey.
Abstract
BACKGROUND: Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy. Vascular endothelial growth factor (VEGF) is a mediator implicated with cell proliferation, differentiation and migration, and monocyte/macrophage chemotaxis. In present study, we aimed to investigate the relationship between VEGF gene polymorphisms (G+405C, T-460C, and A-2578C) and PTC susceptibility. METHODS: DNA was isolated from peripheral blood leukocytes of 127 patients with PTC and 203 healthy controls. Genotyping was performed by real-time PCR. Association of genotypes with susceptibility of PTC was analyzed with multivariate logistic regression adjusted for age, gender and smoking status. RESULTS AND CONCLUSION: In G+405C polymorphism, the frequencies of C allele (related with increased VEGF production) and combined CG+CC genotype were found to be higher (3.5 and 5-fold, respectively) among patients with PTC than controls (P<.001). However, VEGF T-460C and A-2578C polymorphisms are not associated with PTC risk. There was no relationship between VEGF polymorphisms and clinical/laboratory parameters of PTC. Haplotype analysis demonstrated that there was a strong linkage disequilibrium (LD) between -460/-2578 (D'=.89, r2 =.79), weak LD between +405/-460 (D'=.422, r2 =.035), and +405/-2578 (D'=.43, r2 =.038) locuses. Additionally, the +405/-460/-2578 GTA haplotype was found to be protective, whereas CTA haplotype to be related with increased PTC risk. As a conclusion, we suggest that VEGF G+405C polymorphism is associated with increased risk of PTC.
BACKGROUND:Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy. Vascular endothelial growth factor (VEGF) is a mediator implicated with cell proliferation, differentiation and migration, and monocyte/macrophage chemotaxis. In present study, we aimed to investigate the relationship between VEGF gene polymorphisms (G+405C, T-460C, and A-2578C) and PTC susceptibility. METHODS: DNA was isolated from peripheral blood leukocytes of 127 patients with PTC and 203 healthy controls. Genotyping was performed by real-time PCR. Association of genotypes with susceptibility of PTC was analyzed with multivariate logistic regression adjusted for age, gender and smoking status. RESULTS AND CONCLUSION: In G+405C polymorphism, the frequencies of C allele (related with increased VEGF production) and combined CG+CC genotype were found to be higher (3.5 and 5-fold, respectively) among patients with PTC than controls (P<.001). However, VEGFT-460C and A-2578C polymorphisms are not associated with PTC risk. There was no relationship between VEGF polymorphisms and clinical/laboratory parameters of PTC. Haplotype analysis demonstrated that there was a strong linkage disequilibrium (LD) between -460/-2578 (D'=.89, r2 =.79), weak LD between +405/-460 (D'=.422, r2 =.035), and +405/-2578 (D'=.43, r2 =.038) locuses. Additionally, the +405/-460/-2578 GTA haplotype was found to be protective, whereas CTA haplotype to be related with increased PTC risk. As a conclusion, we suggest that VEGFG+405C polymorphism is associated with increased risk of PTC.
Authors: Xiao-Min Yu; Chung-Yau Lo; Alfred King-Yin Lam; Brian Hung-Hin Lang; Pauline Leung; John M Luk Journal: Surgery Date: 2008-12 Impact factor: 3.982
Authors: A-C Gérard; J-F Denef; M-C Many; P Gathy; C de Burbure; M-F van den Hove; F Coppée; C Ledent; I M Colin Journal: J Endocrinol Date: 2003-05 Impact factor: 4.286
Authors: Megan R Haymart; Simone L Glinberg; Jing Liu; Rebecca S Sippel; Juan C Jaume; Herbert Chen Journal: Clin Endocrinol (Oxf) Date: 2008-12-03 Impact factor: 3.478
Authors: A Molinaro; P Orlandi; F Niccolai; P Agretti; G De Marco; E Ferrarini; C Di Cosmo; P Vitti; P Piaggi; T Di Desidero; G Bocci; M Tonacchera Journal: J Endocrinol Invest Date: 2019-08-02 Impact factor: 4.256